Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-29

Study Completion Date

2026-08-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings.

In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction.

The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients

NCT01185405

Invasive Fungal Infection

WITHDRAWN NA

Echinocandins Versus Azoles for Candidemia Treatment

NCT03799172

Candidemia

COMPLETED

Isavuconazole in Critically Ill Patients: Efficacy and Safety

NCT07080359

Fungal Infection Aspergillosis Mucormycosis

NOT_YET_RECRUITING

Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction

NCT07337720

Aspergillosis Invasive

NOT_YET_RECRUITING NA

Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients

NCT05150327

Fungal Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Insufficiency Cirrhosis, Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥18 years old)
* Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024
* At least 3 biological signs of HLH:

* ferritin \> 2000 ng/mL
* triglycerides \> 1.5 g/L
* at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL).